Bufalin inhibits steroid receptor coactivator 1 (SRC-1) and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein, and inhibits cancer cell growth both in vitro and in vivo.

Buparvaquone(Butalex) is a hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone; it is a promising compound for the therapy and prophylaxis of all forms of theileriosis.

Burimamide oxalate is a potent dual H3/H2 receptor antagonist with Ki of 0.07 and 7.8 uM, respectively.

Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well water soluble anti-angiogenic drug that is of potential value in treating choroid neovascularization. Burixafor hydrobromide (TG-0054 hydrobr

BVT 14225 is a new selective 11b-HSD1 inhibitor, it belongs to a class of arylsulfonamidothiazoles with in vitro and in vivo antidiabetic effects

BVT-948 (SPS8I-3) is a noncompetitive, cell-permeable inhibitor of protein tyrosine phosphatases (PTPs) with IC50 of 0.09-1.7 uM. Results show that the effect of BVT948 (BVT.948) is to strengthen the insulin signal and has no effects on the duration of th

BX-320 is a potent, selective and ATP-competitive inhibitor of PDK1 with IC50 of 30 nM, >20-fold selectivity over PKA.

BX-667 is a potent P2Y12 receptor antagonist that blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50=97, 317 and 3000 nM respectively).

BXI-72 (NSC334072) is a potent, selective small molecule Bcl-XL inhibitor that targets the BH3 domain of Bcl-XL (Kd=0.9 nM).

BYK191023 (BYK-191023) is a potent, highly selective inhibitor of inducible nitric-oxide synthase (iNOS) with IC50 of 86 nM, >20-fold selectivity over nNOS and eNOS (IC50=17 and 162 uM).

BYK191023 dihydrochloride (BYK-191023) is a potent, highly selective inhibitor of inducible nitric-oxide synthase (iNOS) with IC50 of 86 nM, >20-fold selectivity over nNOS and eNOS (IC50=17 and 162 uM).

BZ-194 is a small molecule inhibitor of NAADP action that inhibit NAADP-mediated Ca2+ signaling in T cells, neither interferes with Ca2+ mobilization by IP3 or cyclic ADP-ribose nor with capacitative Ca2+ entry.

BzDANP is a small molecule modulator of pre-miR-29a maturation by Dicer, effectively stabilizes the C-bulged RNA and suppresses Dicer-mediated processing of pre-miR-29a in a concentration dependent manner..

Bz-IEGR-pNA is a colorimetric substrate for Factor Xa.

C-021 dihydrochloride is a potent and orally bioavailable CCR4 antagonist with IC50 of 0.14 uM and 0.039 uM for inhibition of chemotaxis in human and mouse, respectively..

C-021 is a potent and orally bioavailable CCR4 antagonist with IC50 of 0.14 uM and 0.039 uM for inhibition of chemotaxis in human and mouse, respectively..

C-215 is a novel inhibitor of mycobacterial membrane protein large 3 (MmpL3) with MIC90 of 16 uM against M. tuberculosis..

C2BA-4(C2BA 4) is a potent, specific human Pregnane X receptor (hPXR) activator with EC50 of 49 nM.

C450-0730 is a potent LuxN antagonist that antagonizes LuxN-AI-1 binding with IC50 of 2.7 uM.

C5-benzyl SAHA is a C5-modified SAHA analog that displays dual selectivity to HDAC6 (IC50=0.27 uM) and HDAC8 (IC50=0.38 uM) over HDAC 1, 2, and 3 (IC50=2.9-5.8 uM).

C87 is a novel small-molecule TNFα inhibitor; potently inhibits TNFα-induced cytotoxicity with an IC50 of 8.73 μM.

Ca2+ channel agonist 1 is a N-type Ca2+ channel activity agonist, with EC50 of 14.23 uM, also inhibits cdk2 kinase activity with EC50 of 3.34 uM.

Cabazitaxel (Jevtana, XRP6258) is a semi-synthetic derivative of a natural taxoid.

Cabergoline, an ergot derivative, is a potent dopamine receptor agonist on D2 receptors.

CAD-031 (CAD31) is a novel brain penetrant, J147-derivative that has enhanced neurogenic activity over J147 in human neural precursor cells (NPCs).

Calcium polystyrene sulfonate is an ion-exchange resin used for reducing blood levels of potassium. Calcium polystyrene sulfonate is used to treat hyperkalemia in patients with chronic kidney disease (CKD).

Calcium-Sensing Receptor Antagonists I is an antagonist of calcium-sensing parathyroid hormone receptors.

Calhex-231 is a potent negative allosteric modulator of CaSR that blocks calcium-mediated activation with IC50 of 0.39 uM.

Calindol hydrochloride is a calcimimetic acting agent and positive allosteric modulator (agonist) of CaSR with EC50 of 0.31 uM (stimulated 3H IP accumulation in CHO cells at 2 mM Ca2+).

Calmidazolium chloride (R 24571) is a calmodulin (CaMK) antagonist, antagonizing CaM-dependent phosphodiesterase and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase with IC50s of 0.15 and 0.35 μM, respectively. Also in anti-cancer re

Calmodulin antagonist. Inhibits Ca2+-calmodulin-dependent phosphodiesterase (IC50 = 28 μM) and myosin light chain kinase (IC50 = 51 μM).

CAM4066 (CAM-4066) is a potent and selective CK2α inhibitor with Kd of 0.32 uM and IC50 of 0.37 uM, shows significantly improved selectivity compared to other CK2α inhibitors. .

CAM4712 (CAM-4712) is a potent and selective CK2α inhibitor with IC50 of 7 uM, exhibits cell growth inhibition in HCT116 cell line with IC50 of 10 uM.

CAMKK2 inhibitor 4t is a potent, selective, orally available, brain-penetrant CAMKK2 inhibitor with pIC50 of 8.5.

Campesterol is a plant sterol with cholesterol lowering and anticarcinogenic effects.

Camptothecin (CPT) is a potent DNA enzyme topoisomerase I (topo I) inhibitor with an IC50 and IC70 of 50 nM and 0.225 μM for breast cancer cell line MDA-MB-231.

CAN-508 is a potent, selective CDK9 inhibitor with IC50 of 0.35 uM (CDK9/cyclin T1), displays >35 fold selectivity over CDK1/2/4/7 (IC50=13.5-70 uM).

Canagliflozin 0.5 H2O(JNJ 28431754; TA 7284) is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM, exhibits 413-fold selectivity over hSGLT1.

Canertinib (CI-1033) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3. CI-1033 shows excellent potency for irreversible inhibition of erbB2 autophosphorylation in MDA-MB

Capecitabine is a tumor-selective fluoropyrimidine carbamate which achieves higher intratumoral 5-FU level with lower toxicity than 5-FU.

Caprooyl tetrapeptide-3 is a derivative of tetrapeptide-3 that is linked to caproic acid.

Capsazepine is a synthetic analogue of the sensory neurone excitotoxin, capsaicin; potent TRPV1 receptor antagonist with IC50 of 562 nM.

Capstafin is a phosphorylation of capsaicinoid derivative that acts as a highly potent, selective inhibitor of STAT5b with Ki of 0.34 uM.

Capzimin (Rpn11 inhibitor 3027) is a derivative of 8TQ, and potent and specific inhibitor of proteasome isopeptidase Rpn11 with IC50 of 0.34 uM, >7-fold improved potency over 8TQ (quinoline-8-thiol).

Carbamazepine, a sodium channel blocker, is an anticonvulsant drug.

Carbinoxamine maleate is a histamine-H1 receptor blocking agent with antihistamine and anticholinergic properties.

Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers). Carbosulfan activation is predominantly catalyzed in humans by CYP3A4.

Carboxy pyridostatin trifluoroacetate salt has the peculiarity to exhibit high molecular specificity for RNA over DNA G4s.

Cardiogenol C is a small cell-permeable molecule that selectively and efficiently induce mouse embryonic stem cells (ESCs) to differentiate into cardiomyocytes with EC50 of 0.1 uM.

Cardionogen 1 (CDNG1) is a small molecule that promotes cardiomyocyte generation by modulating Wnt signaling.

Cardionogen 2 (CDNG2) is a small molecule that promotes cardiomyocyte generation by modulating Wnt signaling.

Cariporide is a selective Na+/H+ exchanger isoform 1 (NHE1) inhibitor (IC50 values are 0.05, 3 and 1000 μM for NHE1, NHE3 and NHE2 respectively).

Cariprazine (RGH-188) is a novel putative antipsychotic drug that exerts partial agonism at dopamine D2/D3 receptors, with preferential binding to D3 receptors, and partial agonism at serotonin 5-HT1A receptors.

CARM1 inhibitor 9 is a potent, selective inhibitor of arginine methyltransferase 1 (CARM1, PRMT4) with IC50 of 94 nM.

CARM1-IN-7g is a potent, selective coactivator-associated arginine methyltransferase 1 (CARM1) with IC50 of 8.6 uM, exhibits lower or no activity against a panel of different PRMTs or HKMTs (>80-fold over PRMT1 and SET7).

Carnostatine (SAN9812) is a specific and highly selective carnosinase (CN1) inhibitor with a Ki of 11 nM.

Carteolol is an antagonist of β-adrenergic receptors (Kd = 13 nM).

CAS 1822358-25-7

Casein Kinase inhibitor A51 (CKIα inhibitor A51) is a novel pan-specific CKI (CSNK1) inhibitor (Kd=0.5-20 nM, CKIα Kd=5.3 nM) that co-targets the transcriptional kinases CDK7 and CDK9, with hardly inhibition of CDK8, CDK13, CDK11a, CDK11b, and CDK19; target both CDK7 and CDK9 with low nM Kd values; induces leukemia cell apoptosis at <160 nM, in correlation to the capacity to stabilize p53; shows high and selective sensitivity against leukemic CFUs in colony-forming unit (CFU) assay, without effect on normal hematopoietic CFUs; blocking CKIα together with CDK7 and/or CDK9 synergistically stabilize p53, deprive leukemia cells of survival and proliferation-maintaining SE-driven oncogenes, induce apoptosis, abolishes the expression of MYC, MDM2, and the anti-apoptotic oncogene MCL1; demonstrates therapeutic efficacy with preserved hematopoiesis and leukemia cure potential in AML mouse models.

Casein Kinase inhibitor A86 (CKIα inhibitor A86) is a novel pan-specific CKI (CSNK1) inhibitor (Kd=1-10 nM, CKIα Kd=9.8 nM) that co-targets the transcriptional kinases CDK7 and CDK9, with hardly inhibition of CDK8, CDK13, CDK11a, CDK11b, and CDK19.

Casopitant (GW679769) is a potent, centrally-acting neurokinin 1 (NK1) receptor antagonist (pKi=9.48) with antidepressant and antiemetic activities.

Casopitant (GW679769) is a potent, centrally-acting neurokinin 1 (NK1) receptor antagonist (pKi=9.48) with antidepressant and antiemetic activities.

CAT639 is an improved analog of ATV399 that exhibits improved β-cell viability and insulin secretion in the rat insulin-producing INS1E cells and primary rat dispersed islet cells, inhibits dimerization of iNOS.

Cathepsin B inhibitor RC1 is a small-molecule that blocks the process of anthrax lethal toxin (LT) cytotoxicity, inhibits enzymatic activity of host cathepsin B that mediates the escape of toxins into the cytoplasm from late endosomes.

CAY10595 is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki of 10 nM.

Cazpaullone (9-Cyano-1-azapaullone) is a derivative of 1-Azakenpaullone, a potent, selective GSK3β inhibitor with IC50 of 8 nM, weakly inhibits CDK1/cyclin B and CDK5/p25 (IC50=0.5 and 0.3 uM).

CB-1158 (INCB-01158) is a potent, selective, oral available Arginase inhibitor with IC50 of 98 nM.

CB5305630 is a potent and noncompetitive IRE1 RNase inhibitor with IC50 of 60 nM in the FRET-derepression assay.

CB-618 (CB 238618) is a novel non-β-lactam β-lactamase inhibitor that potentiates meropenem MIC values against clinical Enterobacteriaceae isolates.

CB-618 (CB 238618) is a novel non-β-lactam β-lactamase inhibitor that potentiates meropenem MIC values against clinical Enterobacteriaceae isolates.

CB-6673567 is a potent, selective Adenylyl Cyclase 1 (AC1) inhibitor with IC50 of 77 uM, displays a 2- to 4-fold isoform selectivity over AC6.

CBB3001 (CBB-3001) is a novel potent, selective histone demethylase LSD1 inhibitor with IC50 of 21.25 uM.

CBK289001 (CBK-289001) is a small molecule inhibitor of Tartrate-resistant acid phosphatase (TRAP/ACP5), demonstrates efficacy in a migration assay and IC50 values from 4 to 125 uM..

CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity.CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL.

CC-671 is a potent, selective, dual TTK (Mps1)/CLK2 inhibitor with IC50 of 5/3 nM, respectively.

CC-885 (CC 885, CC885) is a novel E3 ligase cereblon (CRBN) modulator with potent anti-tumour activity mediated through the degradation of GSPT1.

CC-90003 (CC90003) is a potent and selective, covalent ERK1/2 inhibitor with IC50 of 10-20 nM, demonstrates excellent selectivity in a 258-kinase biochemical assay panel.

CCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays.

CCG 102487 is a CCG-2979 analog that reduces streptokinase (SK) activity with little inhibition of group A streptococcal (GAS) growth.

CCG 2979 is a small molecule inhibitor of gene expression of streptokinase (SK), a critical group A streptococcal (GAS) virulence factor.

CCG-222740 (CCG222740) is a pharmacological inhibitor of MRTF/SRF signalling, shows greater inhibitory effect on MRTF/SRF target genes than MRTF-A inhibitor CCG-203971, with IC50 of 5 uM in fibroblast-mediated collagen contraction assay.

CCG-232601 is a potent (IC50=0.55 uM), orally bioavailable Rho/MKL1/SRF transcriptional pathway that target transcriptional factor MRTF.

CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test.

CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) protein; with greatest potency at RGS4. IC50 value: Target: RGS CCG-63802 is selective amongst RGS proteins, with greatest potency at RGS4.

CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins.

CCI-006 (CCI 006) is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias that share common leukemogenic pathways.

CCI-007 (CCI 007) is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485.

CCMI is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptors (nAChR).

CCR1 inhibitor 19e is a novel potent, selective CCR1 antagonist with IC50 of 6.8 nM, inhibits CCR1chemotaxis in THP-1 cells with IC50 of 28 nM..

CCR10 antagonist 1 is a potent, selective CCR10 antagonist with IC50 of 690 nM.

CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM.

CCR6 inhibitor 35 is a potent and selective CCR6 inhibitor with IC50 of 6.0 nM (hCCR6).

CCT 068127 (CCT68127) is a novel potent inhibitor of CDK2 and CDK9 with IC50 of 10 and 90 nM for CDK2/E and CDK9/T, respectively.

CCT 137690 is a potent inhibitor of Aurora kinases (IC50 values are 0.015, 0.019 and 0.025 μM at Aurora A, Aurora C and Aurora B respectively).

CCT 365623 (CCT365623) hydrochloride is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM.

CCT 365623(CCT365623, CCT-365623) is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM.

CCT007093 is a potent PPM1D (WIP1) inhibitor with IC50 of 8.4 μM.

CCT-01815 is a novel potent inhibitor of Hsp90 ATPase activity with IC50 of 7.1 uM.

CCT020312 is capable of delivering potent, and eukaryotic initiation factor 2-alpha kinase 3 (EIF2AK3) selective, proliferation control and also is an activator of RNA-like endoplasmic reticulum kinase (PERK).

CCT-031374 is a selective β-catenin signaling inhibitor with IC50 of 6.1 uM.

CCT128930 is a potent, selective, ATP-competitive AKT inhibitor with IC50 of 6 nM (AKT2), 28-fold selectivity over the closely related PKA.

CCT129202 is a potent, selective, ATP-competitive pan-Aurora kinase inhibitor with IC50 of 42, 198 and 227 nM for Aurora A, Aurora B and Aurora C, respectively.

CCT241161 is a potent pan-RAF inhibitor with IC50 of 30, 15 and 6 nM for BRAF, V600E-BRAF and C-RAF, also potently inhibits SRC and LCK (IC50=10 and 3 nM, respectively)..

CCT241533 Hcl is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM; shows minimal cross-reactivity against a panel of kinases at 1 uM.

CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with IC50 value of 5 nM.

CCT251921 is a potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. (IC50 data: CDK8:=2.3 nM; CDK19 = 2.6 nM).

CCT367766 is a potent and the third generation heterobifunctional and PROTAC-based pirin targeting protein degradation probe (PDP), depletes pirin protein expression at low concentration. CCT367766 exhibits a moderate affinity for the CRBN-DDB1 complex with an IC50 value of 490 nM. CCT367766 reveals a good affinity for the recombinant pirin and CRBN with Kd values of 55 nM and 120 nM, respectively. CCT367766 provides a potential chemical tool to study a largely unexplored protein[1].

CCX140 is a potent CCR2 antagonist.

CCX-354 (GSK-2941266, CCX354-C, CCX354) is a potent, selective, orally-available CCR1 antagonist for the treatment of inflammatory diseases such as rheumatoid arthritis (RA)..

CD12681 (CD-12681) is a potent, selective RORγ inverse agonist with IC50 of 19 nM, displays no activity against a panel of nuclear receptors (RORα, RARγ, LXRβ, PPARγ and VDR).

CD38 inhibitor 78c is a potent, specific, reversible CD38 inhibitor with Ki of 14.5 nM for recombinant human CD38.

Cdc25 inhibitor S8 is an anti-fungal small molecule that inhibits cdc25 phosphatase with Ki of 140 uM.

Cdc7 inhibitor is a potent inhibitor of Cdc7 kinase with pIC50 of 10.01 against CDC7/DBF4 in TR-FRET assays..

CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.

CDD3506 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.

CDD-450 is an unique inhibitor that selectively blocks p38α activation of proinflammatory kinase MAPK-MK2 while sparing p38α activation of PRAK and ATF2.

CDK12 inhibitor 2 is a potent, selective, non-covalent CDK12 inhibitor with IC50 of 52 nM, displays >192-fold selectivity over CDK2/7/8/9.

CDK12 inhibitor E9 S-isomer (E9, CDK12-IN-E9) is a clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux.

Cdk4/6 Inhibitor IV is a cell-permeable triaminopyrimidine compound acting as a reversible and ATP-competitive inhibitor of Cdk4/6 (IC50 = 1.5 µM and 5.6 µM for Cdk4/D1 and Cdk6/D1, respectively)

CDK5 inhibitor 20-223 (CP 668863) potent, selective, ATP-competitive CDK2/5 inhibitor with IC50 of 6.0 and 8.8 nM for CDK2/CyclinE and CDK5/p35, with little to no activity against CDK1/4/6/7/9.

CDK9 inhibitor HH1 is a novel potent, highly selective CDK9 inhibitor..

CDK9-IN-8 is a highly potent, selective CDK9 inhibitor with IC50 of 12 nM, shows good selectivity in CDKs kinase profiling assay against CDK kinases and cell proliferation inhibition.

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection.

CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM, shows cytotoxicity against a broad CLL samples with mean LD50 of 80 nM.

CDK-IN-2 is a potent and sepecific CDK inhibitor.

CDN1163 (CDN-1163) is a small molecule, allosteric activator of SERCA2, dose-dependently increases the Vmax of SERCA2 Ca2+-ATPase activity in ER microsomes; increases Ca2+-ATPase activity and significantly enhances Ca2+ uptake into the ER, attenuates H2O2-stimulated cell death in HEK cells; improves glucose homeostasis and metabolic parameters, increases glucose tolerance in ob/ob mice; CDN1163 reduces lipid accumulation and decreases lipogenesis in obese mice livers.

CDP-840 (CDP840.

CDP-840 (CDP840.

CDPPB is a potent, selective, brain penetrant positive allosteric modulator of mGlu5 receptor with EC50 of 10 nM and 20 nM for human and rat mGluR5, respectively.

CE-224535 (PF-04905428) is a potent and selective P2X7 receptor antagonist with IC50 of 1.4 nM (inhibition of the release of lL-1b from monocytes stimulated by ATP).

CE-245677 is a potent, selective, orally active, dual Tie2/Trk kinase inhibitor with IC50 of 4.7 nM, 1 nM for Tie2 and TrkA/B, respectively.

CE3F4 is a potent, noncompetitive EPAC1 inhibitor that blocks EPAC1-induced Rap1 activation both in cell-free systems and in intact cells and did not influence protein kinase A holoenzyme activity.

Cecropin B is an antimicrobial peptide with MICs(0.5 to 16 ug/ml) against Gramnegative strains.

Cedazuridine (E7727) is a novel cytidine deaminase inhibitor, and a componet of ASTX727 for treatment of hematologic malignancies..

Cefetamet pivoxil hydrochloride is an oral third generation cephalosporin antibiotic.

Cefmenoxime hydrochloride is a third-generation cephalosporin antibiotic.

Cefoxitin is a beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity.

Cefpiramide sodium (SM-1652; Wy-44635) is a new Pseudomonas-active cephalosporin with a broad spectrum of antibacterial activity.

Cefpirome Sulfate is a fourth generation cephalosporin antibiotic.

Ceftibuten dihydrate is a third-generation cephalosporin antibiotic.

Ceftizoxime is a bacterial inhibitor which acts by interfering with bacterial cell wall synthesis and inhibiting cross-linking of the peptidoglycan.

Cell permeable fluoromethyl ketone (FMK)-derivatized peptides act as effective irreversible Caspase inhibitors with no cytotoxic effects and, therefore, are useful tools for studying Caspase activity.

Cell-permeable, irreversible inhibitor of caspase-3/CPP32; inhibits tumor cell apoptosis. Neuroprotective in rat hippocampus following seizures in vivo.

CeMMEC2 is a novel potent BRD4 inhibitor with IC50 of 0.9 uM, binds to both bromodomains of BRD4, comparably to (S)-JQ1..

Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM.

Cenicriviroc is an orally active, dual CCR2/CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity.

Cenisertib (AS 703569;R763) is a novel potent, orally available inhibitor of Aurora kinases, exhibits signifficant anti-proliferative activity against a wide range of tumor cells both in vitro and in vivo (A549 EC50=9 nM).

Centanafadine (hydrochloride) is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC50s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.

Centanafadine is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC50s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.

Centrinone is a selective and reversible inhibitor of polo-like kinase 4 (Plk4), a serine-threonine protein kinase that initiates centriole/centrosome assembly.

CEP-1347 (KT-7515) is a potent and selective MLK inhibitor that completely rescues motoneurons and inhibits JNK1 activation with IC50 of 20 nM.

CEP-32496 Hcl is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2.

CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.

CEP-7055 is a potent, orally active, pan inhibitor of VEGFR, CEP-7055 is the dimethylglycine ester prodrug of CEP-5214, which inhibits human VEGFR2/KDR kinase, VEGFR1/FLT-1 kinase, and VEGFR3/FLT-4 kinase with IC50 of 18 nM, 12 nM, and 17 nM.

Cephradine is a semi-synthetic cephalosporin antibiotic.

Cerdulatinib(PRT-062070; PRT2070) is an novel oral dual Syk/JAK inhibitor.

Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.

Cevipabulin, also known as TTI-237, an antimicrotubule agent, is a small synthetic molecule of triazolopyrimidine derivative with potential antitumor activity.

CFI02 (CFI-02) is a specific inhibitor of human cytomegalovirus (HCMV) glycoprotein B-mediated fusion with IC50 of 40 nM against laboratory adapted HCMV strain AD169.

CFI-400437 is potent against PLK4 (IC50 = 0.6 nM) and selective against other members of the PLK family (>10 uM).

CFI-401980 is a potent, selective, novel class TTK (Tyrosine Threonine Kinase) inhibitor with Ki of 0.8 nM, HCT116 GI50 of 13 nM.

CFM-2 is a selective non-competitive AMPAR antagonist.

CFM-4.16 is a CARP-1 functional mimetic (CFM) compound bind with CARP-1, stimulates CARP-1 expression and apoptosis.

c-FMS-IN-8 is a potent, selective c-FMS kinase inhibitor with IC50 of 0.8 nM, shows activity in collagen-induced model of arthritis in mice..

CGP37849 is a potent, selective and competitive NMDA receptor antagonist (Ki = 35 nM). Anticonvulsive following oral administration in vivo.

CGP-42112 (CGP42112A) is a highly potent, selective Angiotensin-II subtype 2 receptor(AT2 receptor) agonist with Ki of 0.24 nM.

CGP-53353 (DAPH-7) is a selective inhibitor of PKCβII with IC50 of 0.41 uM, shows weak activity on PKCβI with IC50 of 3.8 uM.

CGP-74514A hydrochloride is a potent CDK1 inhibitor with IC50 of 25 nM.

CGS 21680 is a specific adenosine A2A subtype receptor agonist with Ki of 27 nM.

CGS 27023A (MMI 270) is a potent, orally active MMP inhibitor with Ki of 8-43 nM for MMP1/2/3/9.

Ch-319 (Ch319) is a triphenyltin (IV) carboxylate derivative that modulates AKT/FOXO3a signaling and inhibits progression of prostate cancer.

Chaetocin is a potent, specific, SAM-competitive inhibitor of histone H3K9 methyltransferase (HMT) SU(VAR)3-9 with IC50 of 0.6 uM, no actiivty against H4 Lys20-specific HMT PRSET7 and SET7/9.

Chaetominine , an alkaloidal metabolite with a new framework, was characterized from the solid-substrate culture of Chaetomium sp.

CHDI-390576 (CHDI390576) is a potent, cell permeable and CNS penetrant class IIa HDAC inhibitor with IC50 of 54/60/31/50 nM for HDAC4/5/7/9, respectively.

Chelidonic acid is a component of Chelidonium majus L., used as a mild analgesic, an antimicrobial, an acentral nervous system sedative. Chelidonic acid also shows anti-inflammatory activity. Chelidonic acid has potential to inhibit IL-6 production by blo

CHEMBL333994 is a potent and orally effective Cholecystokinin A (CCK-A) antagonist, with an IC50 of 0.67 nM.

Chemocoxib A is a highly potent, selective, cytotoxic COX-2 inhibitor with IC50 of 290 nM and 90 nM for wt mCOX-2 and R120Q COX-2 mutant respectively.

Chetomin (NSC 289491) is a natural product isolated from Chaetomium species which shows antibacterial and antifungal properties, disrupts the interaction of HIF-1α/p300 at low nanomolar concentrations, strongly increases retinal pigment epithelial cells d

Chiglitazar (CS-038, CS038) is a potent, dual PPARα/γ dual agonist with EC50 of 1.2, 0.08, 1.7 uM for PPARα, PPARγ and PPARδ, respectively.

CHK1-IN-2 is a checkpoint kinase 1 (CHK1) inhibitor, with an IC50 of 6 nM

Chlorantraniliprole is an insecticide that potently and selectively activates insect ryanodine receptor, with EC50s of 40 nM and 50 nM for Drosophila melanogaster and H. virescens ryanodine receptor, and ∼300-fold more potent than that in the mouse myobla

CHMFL-ABL-053 is a potent, selective and orally available Bcr-Abl/Src/p38 kinase inhibitor with IC50 of 70/62/90 nM.

CHMFL-KIT-031 is a highly selective KIT kinase primary V559D mutant inhibitor with IC50/Kd of 28/266 nM, 10-20 fold selectivity over KIT wt.

CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC50, 62.6 nM), PI3Kβ (IC50, 284 nM), PI3

Cholestenone is the intermediate oxidation product of cholesterol.

Choline fenofibrate is a newly developed choline salt of fenofibric acid, a synthetic phenoxy-isobutyric acid derivate with antihyperlipidemic activity that acts as an PPARα agonist.

CHR-3996 (Nanatinostat, VRx-3996, CHR3996, Tractinostat) is a potent, class I-selective, orally active HDAC inhibitor with IC50 of 3-7 nM for HDAC1/2/3.

CHR-6494 is a potent and selective Haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase) inhibitor that blocks H3T3ph phosphorylation.

ChX710 could prime the type I interferon response to cytosolic DNA, which induces the ISRE promoter sequence, specific cellular Interferon-Stimulated Genes (ISGs), and the phosphorylation of Interferon Regulatory Factor (IRF) 3.

CHZ868 is a type II JAK2 inhibitor with an IC50 of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

CI-1044 is a potent, selective and orally bioavailable PDE4 inhibitor with IC50 of 0.27 uM, displays high selectivity for PDE4 versus PDE1/3/5, and no PDE4 subtype (4A-D) selectivities.

CI-966 (PD 126141) is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively.

CI-966 is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively.

CI-976 (PD 128042) is a potent, selective, orally bioavailable inhibitor of ACAT-1 (Acetyl-CoA acetyltransferase 1) with IC50 of 73 nM.

cIAP1 E3 ligase inhibitor D19 (cIAP1 inhibitor D19) is a small-molecule inhibitor of E3 ligase activity of cIAP1, inhibits cIAP1 auto-ubiquitination with IC50 of 14.1 uM, shows no effect on autoubiquitination of BRCA1/BARD1.

cIAP1 E3 ligase inhibitor D19-14 (cIAP1 inhibitor D19-14) is an improved analog of D19, demonstrates significantly increased ability to inhibit cIAP1 autoubiquitination and reduce protein levels of c-MYC in vitro.

CID 1375606 is a surrogate agonist of orphan G protein-coupled receptor GPR27.

CID 9998128 is a potential multi-target drug for the Alzheimer's disease (AD), inhibits the Aβ42 amyloid fibrillization and is capable to clear Aβ42 fibrils.

CID-1067700 is a pan GTPase inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a Ki of 13 nM.

CID3528206 is a potent, small molecule yeast TORC1 inhibitor that inhibits TORC1 activity both in vitro and in vivo with IC50 of 150 nM and 3.9 uM, respectively.